Foreign Private Issuer re-qualification
Renalytix re-qualifies as Foreign Private Issuer following ADS move from Nasdaq to OTCQB.
- Anticipated annual cost savings up to £1.9 million
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 17 January 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, confirms that it has re-qualified for Foreign Private Issuer ("FPI") status.
Following the decision to move the listing of the Company's American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., the ADSs began trading on OTCQB Venture Market under the symbol "RNLXY" on 8 October 2024. The Company anticipates that transferring trading to OTCQB and the re-acquisition of FPI status will provide associated cost savings of up to £1.9 million p.a.
In addition, following re-qualification as an FPI the Company is no longer required to file periodic reports on a quarterly basis. The Company will continue to update shareholders with period end trading updates and financial results for the six month period ending 31 December and fiscal year ending 30 June.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.